SCHEMBL7862256

SCHEMBL7862256

Cc1ccc(N=NN(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
ALDH1A1 P00352 4/20 0.53
NPC1 O15118 6/20 0.50
MAPT P10636 5/20 0.50
RAB9A P51151 5/20 0.50
PKM P14618 3/20 0.44
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 5/20 0.43
MAPK1 P28482 3/20 0.43
STAT3 P40763 1/20 0.43
STAT1 P42224 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 2/20 0.40
ACHE P22303 1/20 0.40
HTR3E A5X5Y0 1/20 0.39
SLC22A2 O15244 1/20 0.39
SLC22A1 O15245 1/20 0.39
SLC22A3 O75751 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17709235 1.00 LMNA (0.53) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL2474220 0.89 LMNA (0.61) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL2474219 0.89 LMNA (0.61) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL17988673 0.88 ALDH1A1 (0.49) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL10411171 0.85 NPC1 (0.43) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL9652831 0.85 NPC1 (0.43) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL17988727 0.84 ALDH1A1 (0.61) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL11883704 0.79 NPC1 (0.49) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL11883699 0.79 NPC1 (0.49) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL1405393 0.78 NPC1 (0.61) LMNAALDH1A1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119868554-A Application of NAT10 as target spot in diagnosis and treatment of NAT10 high expression acute myelogenous leukemia 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 2025-04-25 CN disclosed
US-10646416-B2 Microcapsules containing a gas-releasing photolabile compound and uses thereof FIRMENICH SA (CH) 2020-05-12 US disclosed
US-20160120773-A1 MICROCAPSULES CONTAINING A GAS-RELEASING PHOTOLABILE COMPOUND AND USES THEREOF FIRMENICH SA (CH) 2016-05-05 US disclosed
EP-2999456-A1 MICROCAPSULES CONTAINING A GAS-RELEASING PHOTOLABILE COMPOUND AND USES THEREOF Firmenich SA (CH) 2016-03-30 EP disclosed
WO-2014187874-A1 MICROCAPSULES CONTAINING A GAS-RELEASING PHOTOLABILE COMPOUND AND USES THEREOF FIRMENICH SA (CH) 2014-11-27 WO disclosed
EP-1148105-A2 Composition for film formation, method of film formation, and silica-based film JSR Corporation (JP) 2001-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10646416-B2 Microcapsules containing a gas-releasing photolabile compound and uses thereof ALOX5, TRPA1, FASN LMNA 2011/4885ALDH1A1 4006/4885NPC1 4113/4885
US-20160120773-A1 MICROCAPSULES CONTAINING A GAS-RELEASING PHOTOLABILE COMPOUND AND USES THEREOF ALOX5, TRPA1, FASN LMNA 2011/4885ALDH1A1 4006/4885NPC1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.